orserdu
stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
casodex 50 mg
laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 50 mg
xospata
astellas pharma europe b.v. - gilteritinib fumarate - leukemi, myeloid, akutt - antineoplastiske midler - xospata er indisert som monoterapi for behandling av voksne pasienter som har tilbakefall eller ildfast akutt myelogen leukemi (aml) med en mutasjon flt3.
attribut twin
bayer ag - en salgsenhet inneholder 2 x 300 g attributt sg 70 og 500 ml hussar od.